Epstein–Barr virus latent membrane protein 2 peptide–major histocompatibility complex (EBV LMP2-pMHC)

The Epstein–Barr virus (EBV) latent membrane protein 2 (LMP2) peptide–major histocompatibility complex (pMHC) is a specialized immunological target presented on the surface of EBV-infected B cells and associated malignant cells (PMID: 28811301). LMP2, specifically the LMP2A isoform, is a transmembrane protein that mimics the B-cell receptor (BCR) signal, providing essential survival signals to latently infected B cells (PMID: 15141010). In EBV-associated malignancies like Nasopharyngeal Carcinoma (NPC), Hodgkin Lymphoma, and Post-transplant lymphoproliferative disorder (PTLD), LMP2-derived peptides are processed and presented by MHC Class I molecules (PMID: 30635454). These pMHC complexes are the primary targets for EBV-specific cytotoxic T lymphocytes (CTLs) and modern immunotherapies, including TCR-engineered T cells (TCR-T) and TCR-like antibodies (PMID: 33500253). Because LMP2 is a viral protein not expressed in healthy non-infected tissues, it offers a high degree of tumor specificity for therapeutic intervention (PMID: 23843638). Therapeutic agents targeting these complexes, such as Tabelecleucel, utilize the specificity of the T-cell receptor to identify and eliminate cells harboring the virus (EMA/H/C/005549). However, the clinical utility of these therapies is often constrained by the requirement for specific HLA genotypes in patients, such as HLA-A*02:01 or HLA-A*11:01 (PMID: 25609110). Additionally, tumors may evade detection by downregulating MHC expression or through the selection of peptide variants that escape TCR recognition (PMID: 30635454).

Other names

EBV LMP2-HLA complexLMP2-MHC complexLatent membrane protein 2-MHC complexEBV LMP2 peptide-HLA-A*02:01 complexEBV LMP2 peptide-HLA-A*11:01 complex

Recognition of the viral peptide-MHC complex by T-cell receptors or TCR-mimetic agents to trigger targeted cell lysis.